Schizophrenia: key endpoint results by drug

The key endpoints of Schizophrenia trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Schizophrenia page.

PANSS total, change

PANSS total, change in Schizophrenia: 25 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aripiprazole (Abilify Maintena)-21.5-10.3−11.2400/300 mg · wk 6 · n 162NCT01663532 Phase 3, primary
Aripiprazole (Abilify)-26.7-21.2−5.510 mg/day · wk 6 · n 99NCT00102063 Phase 3, primary
Aripiprazole lauroxil (Aristada)-21.8-9.8−12882 mg · wk 12.14 · n 204NCT01469039 Phase 3, primary
Asenapine-21.7-16.2−5.55 mg BID · wk 6 · n 111NCT01617187 Phase 3, primary
Brexpiprazole (Rexulti)-16.6-13.5−3.12 mg · wk 6 · n 179NCT01393613 Phase 3, primary
Cariprazine (Vraylar)-23-14.3−8.76.0mg · wk 6 · n 154NCT01104766 Phase 3, primary
Iloperidone (Fanapt)-12-7.1−4.9wk 4 · n 283NCT00254202 Phase 3, primary
LB-102 (methylated amisulpride)-14.3-9.3−550 mg QD · wk 4 · n 107NCT06179108 Phase 2, primary
Lumateperone-14.6-15.1+0.542 mg · wk 6 · n 162NCT02469155 Phase 3, primary
Lurasidone-26.5-10.3−16.2160 mg · wk 6 · n 121NCT00790192 Phase 3, primary
Olanzapine (Weltruza)-21.9-12.2−9.8531 mg · wk 8 · n 165NCT05693935 Phase 3, primary
Olanzapine (Zyprexa)-8.84.5−13.3wk 4 · n 21NCT00686998 Phase 2, primary
Olanzapine/samidorphan (Lybalvi)-23.9-17.5−6.4wk 4 · n 132NCT02634346 Phase 3, primary
Paliperidone (Invega)-9.8-7.9−1.9wk 6 · n 54NCT00518323 Phase 3, primary
Paliperidone palmitate (Invega Sustenna)-13.2-2.9−10.3150 mg eq. · wk 13 · n 160NCT00590577 Phase 3, primary
Paliperidone palmitate (Invega Trinza)-1.8-1.6 (PP3M)—wk 52 · n 473NCT03345342 Phase 3, secondary
Perseris-16.5-9.2−7.2120 mg · wk 8 · n 114NCT02109562 Phase 3, primary
Pimavanserin-15.3-13.4−1.9wk 6 · n 193NCT02970292 Phase 3, primary
Quetiapine (Seroquel XR)-24-15.9−8.1wk 6 · n 150NCT01810380 Phase 3, primary
Quetiapine (Seroquel)-24-15.9−8.1wk 6 · n 150NCT01810380 Phase 3, primary
Risperidone (Risperdal Consta)-9.3-1.1 (Quetiapine)—wk 104 · n 326NCT00216476 Phase 3, secondary
Risperidone (Risperdal)-16.5-9.2−7.2120 mg · wk 8 · n 114NCT02109562 Phase 3, primary
tocilizumab-0.5-5.3+4.8wk 12 · n 19NCT02034474 Phase 4, primary
Ulotaront-18.1-14.3−3.8100 mg · wk 6 · n 152NCT04092686 Phase 3, primary
Xanomeline/trospium chloride-14.3-12.2−2.1wk 6 · n 190NCT05145413 Phase 3, primary

Drugs checked with no result here: 48 not reported, 10 trial running, 11 not posted.

CGI-S, change

CGI-S, change in Schizophrenia: 26 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aripiprazole (Abilify Maintena)-1.2-0.5−0.7400/300 mg · wk 6 · n 162NCT01663532 Phase 3, secondary
Aripiprazole (Abilify)-1.2-0.9−0.310 mg/day · wk 6 · n 99NCT00102063 Phase 3, secondary
Aripiprazole lauroxil (Aristada)-0.5-0.9+0.4441-441 mg · wk 52 · n 80NCT01626456 Phase 3, secondary
Asenapine-1.2-1−0.25 mg BID · wk 6 · n 111NCT01617187 Phase 3, secondary
Brexpiprazole (Rexulti)-1.0-0.8−0.22 mg · wk 6 · n 180NCT01393613 Phase 3, secondary
Cariprazine (Vraylar)-1.5-1−0.56.0mg · wk 6 · n 154NCT01104766 Phase 3, secondary
LB-102 (methylated amisulpride)-0.7-0.4−0.350 mg QD · wk 4 · n 91NCT06179108 Phase 2, secondary
Lumateperone-0.8-0.5−0.342 mg · wk 4 · n 148NCT02282761 Phase 3, secondary
Lurasidone-1.1-1−0.140mg · wk 6 · n 122NCT00549718 Phase 3, secondary
Olanzapine (Weltruza)-1.2-0.7−0.5531 mg · wk 8 · n 165NCT05693935 Phase 3, secondary
Olanzapine (Zyprexa Relprevv)-0.4-0.3 (Oral Olanzapine)—wk 104 · n 121NCT00320489 Phase 3, secondary
Olanzapine/samidorphan (Lybalvi)-1.2-0.8−0.4wk 4 · n 132NCT02634346 Phase 3, secondary
Paliperidone (Invega)00±0wk 6 · n 54NCT00518323 Phase 3, secondary
Paliperidone palmitate (Invega Sustenna)-10−1150 mg eq. · wk 13 · n 160NCT00590577 Phase 3, secondary
Paliperidone palmitate (Invega Trinza)00 (PP3M)—wk 52 · n 475NCT03345342 Phase 3, secondary
Perseris0-0.3+0.3wk 4.14 · n 408NCT02203838 Phase 3, secondary
Pimavanserin-0.8-0.7−0.1wk 6 · n 193NCT02970292 Phase 3, secondary
Quetiapine (Seroquel XR)-1.4-0.9−0.5wk 6 · n 150NCT01810380 Phase 3, secondary
Quetiapine (Seroquel)-1.4-0.9−0.5wk 6 · n 150NCT01810380 Phase 3, secondary
Rasagiline (Azilect)4.14.3−0.2wk 4 · n 26NCT00492336 Phase 4, secondary
Risperidone (Risperdal Consta)-0.30.1 (Quetiapine)—wk 104 · n 326NCT00216476 Phase 3, secondary
Risperidone (Risperdal)-0.9-0.5−0.4120 mg · wk 8 · n 114NCT02109562 Phase 3, secondary
Roluperidone-0.3-0.1−0.264 mg · wk 4 · n 171NCT03397134 Phase 3, secondary
Ulotaront-0.9-0.8−0.2100 mg · wk 6 · n 152NCT04092686 Phase 3, secondary
Xanomeline/trospium chloride-0.6-0.5−0.1wk 6 · n 190NCT05145413 Phase 3, secondary
Ziprasidone-1.2-1.2 (Haloperidol)—wk 0.43 · n 188NCT00723606 Phase 3, secondary

Drugs checked with no result here: 48 not reported, 10 trial running, 10 not posted.

PANSS response

PANSS response in Schizophrenia: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aripiprazole (Abilify Maintena)37%14.3%+22.7400/300 mg · wk 10 · n 162NCT01663532 Phase 3, secondary
Asenapine39.3%20.7%+18.65 mg BID · wk 6 · n 173NCT01098110 Phase 3, secondary
Brexpiprazole (Rexulti)38.5%31.7%+6.82 mg · wk 6 · n 179NCT01393613 Phase 3, secondary
Cannabidiol (Epidiolex)28.6%13.6%+151000 mg/Day · wk 6.14 · n 42NCT02006628 Phase 2, primary
Olanzapine (Zyprexa)31.7%a44.7% (amisulpride)——NCT03510325 Phase 3, primary
Paliperidone (Invega)67.9%76.3% (Aripiprazole)—wk 8 · n 112NCT01009047 Phase 3, secondary
Quetiapine (Seroquel XR)62.7%32.1%+30.6wk 6 · n 150NCT01810380 Phase 3, secondary
Quetiapine (Seroquel)62.7%32.1%+30.6wk 6 · n 150NCT01810380 Phase 3, secondary
Ulotaront64.6%44%+20.6wk 4 · n 96NCT02969382 Phase 2, secondary

Drugs checked with no result here: 51 not reported, 13 trial running, 21 not posted.

PSP, change

PSP, change in Schizophrenia: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aripiprazole (Abilify Maintena)12.35.2+7.1400/300 mg · wk 10 · n 139NCT01663532 Phase 3, secondary
Brexpiprazole (Rexulti)10.58.5+22 mg · wk 6 · n 170NCT01393613 Phase 3, secondary
Olanzapine (Weltruza)10.65.6+5531 mg · wk 8 · n 165NCT05693935 Phase 3, secondary
Paliperidone (Invega)12.212.2 (Aripiprazole)—wk 8 · n 112NCT01009047 Phase 3, secondary
Paliperidone palmitate (Invega Sustenna)8.31.7+6.6150 mg eq. · wk 13 · n 160NCT00590577 Phase 3, secondary
Paliperidone palmitate (Invega Trinza)11.1 (PP3M)—wk 52 · n 473NCT03345342 Phase 3, secondary
Pimavanserin6.85.7+1.1wk 6 · n 193NCT02970292 Phase 3, secondary
Quetiapine (Seroquel XR)15.39.4+5.9wk 6 · n 138NCT01810380 Phase 3, secondary
Quetiapine (Seroquel)15.39.4+5.9wk 6 · n 138NCT01810380 Phase 3, secondary
Risperidone (Risperdal Consta)5.36.0 (Risperidone Tablets)—wk 52 · n 17NCT00992407 Phase 4, primary
Roluperidone3.21.2+264 mg · wk 4 · n 162NCT03397134 Phase 3, secondary
Xanomeline/trospium chloride5.35.9−0.6wk 6 · n 190NCT05145413 Phase 3, secondary

Drugs checked with no result here: 51 not reported, 13 trial running, 18 not posted.

Relapse (% of patients) (maintenance)

Relapse (% of patients) in Schizophrenia: 8 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aripiprazole (Abilify Maintena)10%39.6%−29.6wk 52 · n 269NCT00705783 Phase 3, secondary
Aripiprazole (Abilify)19.4%37.5%−18.1wk 52 · n 98NCT01149655 Phase 3, primary
Brexpiprazole (Rexulti)13.5%38.5%−24.9wk 52 · n 96NCT01668797 Phase 3, secondary
Lumateperone16.4%a38.6%−22.2—NCT04959032 Phase 3, primary
Lurasidone20.9%26.6% (Quetiapine)—wk 52 · n 139NCT00789698 Phase 3, primary
Olanzapine (Zyprexa Relprevv)20.1%18.5% (Oral Olanzapine)—n 264NCT00320489 Phase 3, secondary
Risperidone (Risperdal Consta)5%32.6% (Risperidone)—wk 52 · n 40NCT00330551 Phase 4, primary
Risperidone (Uzedy)7.1%29.3%−22.2q1m · n 183NCT03503318 Phase 3, primary

Drugs checked with no result here: 52 not reported, 14 trial running, 20 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 94 approved or late-stage drugs with a featured trial in Schizophrenia were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.